Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Red de investigación Renal

IP: Daniel Serón Micas
Collaborators: Joan López Hellin, Red de investigación Renal, Francesc Moreso Mateos, Enric Trilla Herrera, Natalia Ramos Terrades, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá, Manel Perelló Carrascosa
Funding agency: Instituto de Salud Carlos III
Funding: 92250
Reference: RD12/0021/0013
Duration: 01/01/2013 - 31/12/2016

Kidney and sex hormones: Novel insights into development and progression of the metabolic syndrome

IP: Kidney and sex hormones: Novel insights into development and progression of the metabolic syndrome
Collaborators: Joan López Hellin, Concepció Jacobs Cachá, Andrea Caballero Garralda
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 266200
Reference: SAF2011-29506
Duration: 01/01/2012 - 31/12/2014

Ministerio de Ciencia

Acción andrógénica y función renal: Implicación de la Kidney androgen-regulated protein (KAP)

IP: Acción andrógénica y función renal: Implicación de la Kidney androgen-regulated protein (KAP)
Collaborators: Joan López Hellin, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 18000
Reference: SENEFRO/01/08
Duration: 01/02/2009 - 31/01/2011

Patologia Cel·lular

IP: Patologia Cel·lular
Collaborators: Joan López Hellin, Ramón Vilalta Casas, Alvaro Domingo Madrid Aris, Francesc Moreso Mateos, Enric Trilla Herrera, Daniel Serón Micas, Luis Enrique Lara Moctezuma, Concepció Jacobs Cachá, Carles Xavier Raventós Busquets
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2009 SGR 75
Duration: 01/01/2010 - 30/04/2014

Related news

The new system, made of cellulose and chitosan, enables sustained release of docetaxel and has demonstrated antitumor activity in preclinical models of ovarian cancer and glioblastoma.

The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.

The European COMFORT project, in collaboration with VHIR, IDIAPJGol and ICS primary care, promotes the transformation of current blood collection models.

Related professionals

Dominguez Gascon, Alba

Dominguez Gascon, Alba

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more
Samanes Agreda, Gloria

Samanes Agreda, Gloria

Research technician
Pediatric Neurology
Read more
Nogue Pich, Berta

Nogue Pich, Berta

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more
Vidal Otero, Jana

Vidal Otero, Jana

Research technician
Basic, Translational and Clinical Pharmacy Research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.